Ascendis Pharma A/S (NASDAQ:ASND) Rating Lowered to “Sell” at StockNews.com

StockNews.com downgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a sell rating in a research report report published on Tuesday morning.

Several other research firms have also recently commented on ASND. Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, November 4th. JPMorgan Chase & Co. decreased their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. Bank of America increased their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Evercore ISI increased their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a report on Tuesday, September 17th. Finally, TD Cowen increased their price objective on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a report on Monday, October 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $126.51 on Tuesday. The company has a 50-day simple moving average of $132.30 and a 200-day simple moving average of $132.70. The firm has a market capitalization of $7.67 billion, a P/E ratio of -13.59 and a beta of 0.66. Ascendis Pharma A/S has a 52 week low of $90.13 and a 52 week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. As a group, equities analysts forecast that Ascendis Pharma A/S will post -7.35 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Large investors have recently bought and sold shares of the business. Groupama Asset Managment bought a new position in Ascendis Pharma A/S during the third quarter valued at $60,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after acquiring an additional 336,976 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Ascendis Pharma A/S by 6.8% during the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after acquiring an additional 267,881 shares in the last quarter. Acadian Asset Management LLC increased its holdings in Ascendis Pharma A/S by 1,461.1% in the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after buying an additional 234,446 shares during the period. Finally, Avoro Capital Advisors LLC increased its holdings in Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after buying an additional 229,995 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.